Oxidative stress in diabetes and Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 16, Issue 4, 2009, Pages 763-774

  Reddy, V Prakash ^a   Zhu, Xiongwei ^b   Perry, George ^b,c   Smith, Mark A ^b  

^a MISSOURI UNIVERSITY OF SCIENCE AND TECHNOLOGY   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c University of San Antonio   (United States)

Author keywords

Advanced glycation end products; AGE inhibitors; Alzheimer's disease; Diabetes; Glycation; Maillard reaction; Oxidative stress; Protein crosslinks

Indexed keywords

2 ISOPROPYLIDENEHYDRAZONO 4 OXO 5 THIAZOLIDINYLACETANILIDE; 4 (4 BROMOPHENYL) 2 (4 PYRIDOYLHYDRAZINO) 1,3 THIAZOLE; 6 N CARBOXYMETHYLLYSINE; ACETYLCYSTEINE; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT INHIBITOR; ALAGEBRIUM; AMINOGUANIDINE; ANTIDIABETIC AGENT; CARNOSINE; CLIOQUINOL; COCARBOXYLASE; DEFEROXAMINE; HOMOCARNOSINE; INSULIN; N PHENACYL 1,3 THIAZOLIUM BROMIDE; NUCLEIC ACID; PERINDOPRIL; PYRIDOXAMINE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; ROSIGLITAZONE; THIAZOLE DERIVATIVE; THIOCTIC ACID; UNCLASSIFIED DRUG; ANTIOXIDANT;

ALZHEIMER DISEASE; CELLULAR IMMUNITY; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE COURSE; DRUG STRUCTURE; HUMAN; LIPID PEROXIDATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT; ANIMAL; CHEMISTRY; DRUG EFFECT; PATHOPHYSIOLOGY; PHYSIOLOGY;

ALZHEIMER DISEASE; ANIMALS; ANTIOXIDANTS; DIABETES MELLITUS; HUMANS; OXIDATIVE STRESS;

EID: 67649678412     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2009-1013     Document Type: Review

References (111)

1. Moreira PI, Nunomura A, Zhu X, Smith MA, Perry G (2007) Oxidative damage is the earliest change of Alzheimer disease: therapeutic opportunities In Research Progress in Alzheimer's Disease and Dementia, Sun M-K, ed. Nova Science Publishers, Inc., New York, pp. 301-317.
2. Smith MA, Sayre LM, Monnier VM, Perry G (1995) Radical AGEing in Alzheimer's disease. Trends Neurosci 18, 172-176.
3. Smith MA, Richey Harris PL, Sayre LM, Beckman JS, Perry G (1997) Widespread peroxynitrite-mediated damage in Alzheimer's disease. J Neurosci 17, 2653-2657.
4. McShea A, Harris PL, Webster KR, Wahl AF, Smith MA (1997) Abnormal expression of the cell cycle regulators P16 and CDK4 in Alzheimer's disease. Am J Pathol 150, 1933-1939. (Pubitemid 27233067)
5. Ogawa O, Zhu X, Lee HG, Raina A, Obrenovich ME, Bowser R, Ghanbari HA, Castellani RJ, Perry G, Smith MA (2003) Ectopic localization of phosphorylated histone H3 in Alzheimer's disease: a mitotic catastrophe? Acta Neuropathol (Berl) 105, 524-528. (Pubitemid 36798850)
6. Harris PL, Zhu X, Pamies C, Rottkamp CA, Ghanbari HA, McShea A, Feng Y, Ferris DK, Smith MA (2000) Neuronal polo-like kinase in Alzheimer disease indicates cell cycle changes. Neurobiol Aging 21, 837-841.
7. Zhu X, Lee HG, Perry G, Smith MA (2007) Alzheimer disease, the two-hit hypothesis: an update. Biochim Biophys Acta 1772, 494-502. (Pubitemid 46400383)
8. Zhu X, Raina AK, Perry G, Smith MA (2004) Alzheimer's disease: the two-hit hypothesis. Lancet Neurol 3, 219-226.
9. Zhu X, Perry G, Smith MA (2008) Two hits and you're out? A novel mechanistic hypothesis of Alzheimer disease In Advances in Behavioral Biology, Volume 57, Advances in Alzheimer's and Parkinson's Disease: Insights, Progress and Perspectives, Fisher A, Memo M, Stocchi F, Hanin I, eds. Springer Science + Business Media, LLC, New York, pp. 191-204.
10. Schmidt AM, Stern D (2000) Atherosclerosis and diabetes: the RAGE connection. Curr Atheroscler Rep 2, 430-436.
11. Smith MA, Sayre LM, Perry G (1996) Diabetes mellitus and Alzheimer's disease: glycation as a biochemical link. Diabetologia 39, 247.
12. Zhu X, Su B, Wang X, Smith MA, Perry G (2007) Causes of oxidative stress in Alzheimer disease. Cell Mol Life Sci 64, 2202-2210. (Pubitemid 47347959)
13. Nakabeppu Y, Tsuchimoto D, Ichinoe A, Ohno M, Ide Y, Hirano S, Yoshimura D, Tominaga Y, Furuichi M, Sakumi K (2004) Biological significance of the defense mechanisms against oxidative damage in nucleic acids caused by reactive oxygen species: from mitochondria to nuclei. Ann N Y Acad Sci 1011, 101-111. (Pubitemid 38608396)
14. Reddy VP, Beyaz A, Perry G, Cooke MS, Sayre LM, Smith MA (2007) The role of oxidative damage to nucleic acids in the pathogenesis of neurological disease In Oxidative Damage to Nucleic Acids, Evans MD, Cooke MS, eds. Landes Bioscience and Springer Science+Business Media, LLC, Austin, pp. 123-140.
15. Stadtman ER (2001) Protein oxidation in aging and agerelated diseases. Ann N Y Acad Sci 928, 22-38. (Pubitemid 32386064)
16. Sayre LM, Lin D, Yuan Q, Zhu X, Tang X (2006) Protein adducts generated from products of lipid oxidation: focus on HNE and one. Drug Metab Rev 38, 651-675. (Pubitemid 44903261)
17. Yan SF, Barile GR, D'Agati V, Du Yan S, Ramasamy R, Schmidt AM (2007) The biology of RAGE and its ligands: uncovering mechanisms at the heart of diabetes and its complications. Curr Diab Rep 7, 146-153. (Pubitemid 46730741)
18. Bierhaus A, Humpert PM, Morcos M, Wendt T, Chavakis T, Arnold B, Stern DM, Nawroth PP (2005) Understanding RAGE, the receptor for advanced glycation end products. J Mol Med 83, 876-886. (Pubitemid 41598688)
19. Chen X, Walker DG, Schmidt AM, Arancio O, Lue LF, Yan SD (2007) RAGE: a potential target for Abeta-mediated cellular perturbation in Alzheimer's disease. Curr Mol Med 7, 735-742.
20. Mecocci P, Mariani E, Polidori MC, Hensley K, Butterfield DA (2008) Antioxidant agents in Alzheimer's disease. Cent Nerv Syst Agents Med Chem 8, 48-63.
21. Leeuwenburgh C, Hansen P, Shaish A, Holloszy JO, Heinecke JW (1998) Markers of protein oxidation by hydroxyl radical and reactive nitrogen species in tissues of aging rats. Am J Physiol 274, R453-461. (Pubitemid 28103032)
22. Matthews RT, Beal MF (1996) Increased 3-nitrotyrosine in brains of Apo E-deficient mice. Brain Res 718, 181-184.
23. Stadler K, Bonini MG, Dallas S, Jiang J, Radi R, Mason RP, Kadiiska MB (2008) Involvement of inducible nitric oxide synthase in hydroxyl radical-mediated lipid peroxidation in streptozotocin-induced diabetes. Free Radic Biol Med 45, 866-874.
24. Smith MA, Harris PL, Sayre LM, Perry G (1997) Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci U S A 94, 9866-9868.
25. Sayre LM, Perry G, Harris PL, Liu Y, Schubert KA, Smith MA (2000) In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer's disease: a central role for bound transition metals. J Neurochem 74, 270-279. (Pubitemid 30012778)
26. Caulfield JL, Wishnok JS, Tannenbaum SR (2003) Nitric oxide-induced interstrand cross-links in DNA. Chem Res Toxicol 16, 571-574.
27. Chen HJ, Chiu WL, Lin WP, Yang SS (2008) Investigation of DNA-protein cross-link formation between lysozyme and oxanine by mass spectrometry. Chembiochem 9, 1074-1081.
28. Chen HJ, Hsieh CJ, Shen LC, Chang CM (2007) Characterization of DNA-protein cross-links induced by oxanine: cellular damage derived from nitric oxide and nitrous acid. Biochemistry (Mosc) 46, 3952-3965.
29. Edfeldt NB, Harwood EA, Sigurdsson ST, Hopkins PB, Reid BR (2004) Solution structure of a nitrous acid induced DNA interstrand cross-link. Nucleic Acids Res 32, 2785-2794.
30. Reddy VP, Obrenovich ME, Atwood CS, Perry G, Smith MA (2002) Involvement of Maillard reactions in Alzheimer disease. Neurotox Res 4, 191-209. (Pubitemid 34679370)
31. Ulrich P, Cerami A (2001) Protein glycation, diabetes, and aging. Recent Prog Horm Res 56, 1-21.
32. Spiteller G (2008) Peroxyl radicals are essential reagents in the oxidation steps of the Maillard reaction leading to generation of advanced glycation end products. Ann NY Acad Sci 1126, 128-133.
33. Reddy VP, Beyaz A (2006) Inhibitors of the Maillard reaction and AGE breakers as therapeutics for multiple diseases. Drug Discov Today 11, 646-654.
34. Rabbani N, Thornalley PJ (2008) The dicarbonyl proteome: proteins susceptible to dicarbonyl glycation at functional sites in health, aging, and disease. Ann N Y Acad Sci 1126, 124-127. (Pubitemid 351589305)
35. Synold T, Xi B, Wuenschell GE, Tamae D, Figarola JL, Rahbar S, Termini J (2009) Advanced glycation end products of DNA: Quantification of N2-(1-carboxyethyl)-2'-deoxyguanosine in biological samples by liquid chromatography electrospray ionization tandem mass spectrometry. Chem Res Toxicol, in press.
36. Sell DR, Strauch CM, Shen W, Monnier VM (2008) Aging, diabetes, and renal failure catalyze the oxidation of lysyl residues to 2-aminoadipic acid in human skin collagen: evidence for metal-catalyzed oxidation mediated by alpha-dicarbonyls. Ann N Y Acad Sci 1126, 205-209. (Pubitemid 351589327)
37. Seidel W, Pischetsrieder M (1998) DNA-glycation leads to depurination by the loss of N2-carboxyethylguanine in vitro. Cell Mol Biol (Noisy-le-grand) 44, 1165-1170.
38. Nagai R, Fujiwara Y, Mera K, Yamagata K, Sakashita N, Takeya M (2008) Immunochemical detection of Nepsilon-(carboxyethyl)lysine using a specific antibody. J Immunol Methods 332, 112-120.
39. Smith MA, Taneda S, Richey PL, Miyata S, Yan SD, Stern D, Sayre LM, Monnier VM, Perry G (1994) Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc Natl Acad Sci U S A 91, 5710-5714. (Pubitemid 24174398)
40. Yan SD, Chen X, Schmidt AM, Brett J, Godman G, Zou YS, Scott CW, Caputo C, Frappier T, Smith MA (1994) Glycated tau protein in Alzheimer disease: a mechanism for induction of oxidant stress. Proc Natl Acad Sci U S A 91, 7787-7791. (Pubitemid 24238270)
41. Castellani RJ, Harris PL, Sayre LM, Fujii J, Taniguchi N, Vitek MP, Founds H, Atwood CS, Perry G, Smith MA (2001) Active glycation in neurofibrillary pathology of Alzheimer disease: N(epsilon)-(carboxymethyl) lysine and hexitollysine. Free Radic Biol Med 31, 175-180. (Pubitemid 32607584)
42. Takeda A, Yasuda T, Miyata T, Goto Y, Wakai M, Watanabe M, Yasuda Y, Horie K, Inagaki T, Doyu M, Maeda K, Sobue G (1998) Advanced glycation end products co-localized with astrocytes and microglial cells in Alzheimer's disease brain. Acta Neuropathol 95, 555-558. (Pubitemid 28254562)
43. Takeuchi M, Makita Z (2001) Alternative routes for the formation of immunochemically distinct advanced glycation end-products in vivo. Curr Mol Med 1, 305-315. (Pubitemid 33772959)
44. Ahmed N, Argirov OK, Minhas HS, Cordeiro CA, Thornalley PJ (2002) Assay of advanced glycation endproducts (AGEs): surveying AGEs by chromatographic assay with derivatization by 6-aminoquinolyl-N-hydroxysuccinimidylcarbamate and application to Nepsilon-carboxymethyllysine- and Nepsilon-(1-carboxyethyl) lysine-modified albumin. Biochem J 364, 1-14. (Pubitemid 34538940)
45. Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, Jones PK, Ghanbari H, Wataya T, Shimohama S, Chiba S, Atwood CS, Petersen RB, Smith MA (2001) Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 60, 759-767. (Pubitemid 32678256)
46. Maczurek A, Shanmugam K, Munch G (2008) Inflammation and the redox-sensitive AGE-RAGE pathway as a therapeutic target in Alzheimer's disease. Ann N Y Acad Sci 1126, 147-151. (Pubitemid 351589288)
47. Ramasamy R, Yan SF, Herold K, Clynes R, Schmidt AM (2008) Receptor for advanced glycation end products: fundamental roles in the inflammatory response: winding the way to the pathogenesis of endothelial dysfunction and atherosclerosis. Ann N Y Acad Sci 1126, 7-13. (Pubitemid 351589318)
48. Yan SF, Ramasamy R, Schmidt AM (2008) Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications. Nat Clin Pract Endocrinol Metab 4, 285-293. (Pubitemid 351571138)
49. Buetler TM, Leclerc E, Baumeyer A, Latado H, Newell J, Adolfsson O, Parisod V, Richoz J, Maurer S, Foata F, Piguet D, Junod S, Heizmann CW, Delatour T (2008) N(epsilon)-carboxymethyllysine-modified proteins are unable to bind to RAGE and activate an inflammatory response. Mol Nutr Food Res 52, 370-378.
50. Yamagishi S, Nakamura K, Matsui T, Noda Y, Imaizumi T (2008) Receptor for advanced glycation end products (RAGE): a novel therapeutic target for diabetic vascular complication. Curr Pharm Des 14, 487-495.
51. Diau GY, Hsieh AT, Sarkadi-Nagy EA, Wijendran V, Nathanielsz PW, Brenna JT (2005) The influence of long chain polyunsaturate supplementation on docosahexaenoic acid and arachidonic acid in baboon neonate central nervous system. BMC Med 3, 11. (Pubitemid 41534984)
52. Montine TJ, Milatovic D, Gupta RC, Valyi-Nagy T, Morrow JD, Breyer RM (2002) Neuronal oxidative damage from activated innate immunity is EP2 receptor-dependent. J Neurochem 83, 463-470. (Pubitemid 35191411)
53. Neely MD, Boutte A, Milatovic D, Montine TJ (2005) Mechanisms of 4-hydroxynonenal-induced neuronal microtubule dysfunction. Brain Res 1037, 90-98. (Pubitemid 40362384)
54. Sayre LM, Zelasko DA, Harris PL, Perry G, Salomon RG, Smith MA (1997) 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J Neurochem 68, 2092-2097. (Pubitemid 27176147)
55. Liu Q, Raina AK, Smith MA, Sayre LM, Perry G (2003) Hydroxynonenal, toxic carbonyls, and Alzheimer disease. Mol Aspects Med 24, 305-313. (Pubitemid 36945030)
56. Takeda A, Smith MA, Avila J, Nunomura A, Siedlak SL, Zhu X, Perry G, Sayre LM (2000) In Alzheimer's disease, heme oxygenase is coincident with Alz50, an epitope of tau induced by 4-hydroxy-2-nonenal modification. J Neurochem 75, 1234-1241. (Pubitemid 30660513)
57. Long EK, Murphy TC, Leiphon LJ, Watt J, Morrow JD, Milne GL, Howard JR, Picklo MJ, Sr. (2008) Trans-4-hydroxy-2-hexenal is a neurotoxic product of docosahexaenoic (22:6; n-3) acid oxidation. J Neurochem 105, 714-724.
58. Stewart BJ, Doorn JA, Petersen DR (2007) Residue-specific adduction of tubulin by 4-hydroxynonenal and 4-oxononenal causes cross-linking and inhibits polymerization. Chem Res Toxicol 20, 1111-1119.
59. Lin D, Lee HG, Liu Q, Perry G, Smith MA, Sayre LM (2005) 4-Oxo-2-nonenal is both more neurotoxic and more protein reactive than 4-hydroxy-2-nonenal. Chem Res Toxicol 18, 1219-1231. (Pubitemid 41170246)
60. Carbone DL, Doorn JA, Kiebler Z, Petersen DR (2005) Cysteine modification by lipid peroxidation products inhibits protein disulfide isomerase. Chem Res Toxicol 18, 1324-1331. (Pubitemid 41174583)
61. Calabrese V, Mancuso C, Sapienza M, Puleo E, Calafato S, Cornelius C, Finocchiaro M, Mangiameli A, Di Mauro M, Stella AM, Castellino P (2007) Oxidative stress and cellular stress response in diabetic nephropathy. Cell Stress Chaperones 12, 299-306.
62. Casado A, Encarnacion Lopez-Fernandez M, Concepcion Casado M, de La Torre R (2008) Lipid peroxidation and antioxidant enzyme activities in vascular and Alzheimer dementias. Neurochem Res 33, 450-458. (Pubitemid 351230446)
63. Kuhla B, Boeck K, Luth HJ, Schmidt A, Weigle B, Schmitz M, Ogunlade V, Munch G, Arendt T (2006) Age-dependent changes of glyoxalase I expression in human brain. Neurobiol Aging 27, 815-822.
64. Smith MA, Kutty RK, Richey PL, Yan SD, Stern D, Chader GJ, Wiggert B, Petersen RB, Perry G (1994) Heme oxygenase-1 is associated with the neurofibrillary pathology of Alzheimer's disease. Am J Pathol 145, 42-47. (Pubitemid 24217481)
65. Premkumar DR, Smith MA, Richey PL, Petersen RB, Castellani R, Kutty RK, Wiggert B, Perry G, Kalaria RN (1995) Induction of heme oxygenase-1 mRNA and protein in neocortex and cerebral vessels in Alzheimer's disease. J Neurochem 65, 1399-1402.
66. Annangudi SP, Deng Y, Gu X, Zhang W, Crabb JW, Salomon RG (2008) Low-density lipoprotein has an enormous capacity to bind (E)-4-hydroxynon-2-enal (HNE): detection and characterization of lysyl and histidyl adducts containing multiple molecules of HNE. Chem Res Toxicol 21, 1384-1395.
67. Wataya T, Nunomura A, Smith MA, Siedlak SL, Harris PL, Shimohama S, Szweda LI, Kaminski MA, Avila J, Price DL, Cleveland DW, Sayre LM, Perry G (2002) High molecular weight neurofilament proteins are physiological substrates of adduction by the lipid peroxidation product hydroxynonenal. J Biol Chem 277, 4644-4648. (Pubitemid 34968493)
68. Liu Q, Smith MA, Avila J, DeBernardis J, Kansal M, Takeda A, Zhu X, Nunomura A, Honda K, Moreira PI, Oliveira CR, Santos MS, Shimohama S, Aliev G, de la Torre J, Ghanbari HA, Siedlak SL, Harris PL, Sayre LM, Perry G (2005) Alzheimer-specific epitopes of tau represent lipid peroxidation-induced conformations. Free Radic Biol Med 38, 746-754. (Pubitemid 40249745)
69. Gomez-Ramos A, Diaz-Nido J, Smith MA, Perry G, Avila J (2003) Effect of the lipid peroxidation product acrolein on tau phosphorylation in neural cells. J Neurosci Res 71, 863-870. (Pubitemid 36293007)
70. Santa-Maria I, Smith MA, Perry G, Hernandez F, Avila J, Moreno FJ (2005) Effect of quinones on microtubule polymerization: a link between oxidative stress and cytoskeletal alterations in Alzheimer's disease. Biochim Biophys Acta 1740, 472-480. (Pubitemid 40804759)
71. Liu Z, Minkler PE, Sayre LM (2003) Mass spectroscopic characterization of protein modification by 4-hydroxy-2-(E)-nonenal and 4-oxo-2-(E)-nonenal. Chem Res Toxicol 16, 901-911. (Pubitemid 36899005)
72. Leonarduzzi G, Robbesyn F, Poli G (2004) Signaling kinases modulated by 4-hydroxynonenal. Free Radic Biol Med 37, 1694-1702.
73. Zhu X, Lee HG, Raina AK, Perry G, Smith MA (2002) The role of mitogen-activated protein kinase pathways in Alzheimer's disease. Neurosignals 11, 270-281. (Pubitemid 37494394)
74. Zhu X, Castellani RJ, Takeda A, Nunomura A, Atwood CS, Perry G, Smith MA (2001) Differential activation of neuronal ERK, JNK/SAPK and p38 in Alzheimer disease: the 'two hit' hypothesis. Mech Ageing Dev 123, 39-46.
75. Tamagno E, Robino G, Obbili A, Bardini P, Aragno M, Parola M, Danni O (2003) H2O2 and 4-hydroxynonenal mediate amyloid beta-induced neuronal apoptosis by activating JNKs and p38MAPK. Exp Neurol 180, 144-155.
76. Reddy PH, Beal MF (2008) Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. Trends Mol Med 14, 45-53.
77. Hirai K, Aliev G, Nunomura A, Fujioka H, Russell RL, Atwood CS, Johnson AB, Kress Y, Vinters HV, Tabaton M, Shimohama S, Cash AD, Siedlak SL, Harris PL, Jones PK, Petersen RB, Perry G, Smith MA (2001) Mitochondrial abnormalities in Alzheimer's disease. J Neurosci 21, 3017-3023.
78. SwerdlowRH, KhanSM(2004)Amitochondrial cascade hypothesis for sporadic Alzheimer's disease. Med Hypotheses 63, 8-20. (Pubitemid 38887104)
79. Onyango I, Khan S, Miller B, Swerdlow R, Trimmer P, Bennett P, Jr. (2006) Mitochondrial genomic contribution to mitochondrial dysfunction in Alzheimer's disease. J Alzheimers Dis 9, 183-193.
80. Moreira PI, Harris PL, Zhu X, Santos MS, Oliveira CR, Smith MA, Perry G (2007) Lipoic acid and N-acetyl cysteine decrease mitochondrial-related oxidative stress in Alzheimer disease patient fibroblasts. J Alzheimers Dis 12, 195-206. (Pubitemid 47509369)
81. Brownlee M (2005) The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54, 1615-1625.
82. Takuma K, Yao J, Huang J, Xu H, Chen X, Luddy J, Trillat AC, Stern DM, Arancio O, Yan SS (2005) ABAD enhances Abeta-induced cell stress via mitochondrial dysfunction. FASEB J 19, 597-598.
83. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I, Brownlee M (2000) Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404, 787-790. (Pubitemid 30212409)
84. Ghanbari HA, Ghanbari K, Harris PL, Jones PK, Kubat Z, Castellani RJ, Wolozin BL, Smith MA, Perry G (2004) Oxidative damage in cultured human olfactory neurons from Alzheimer's disease patients. Aging Cell 3, 41-44. (Pubitemid 40246661)
85. Perry G, Castellani RJ, Smith MA, Harris PL, Kubat Z, Ghanbari K, Jones PK, Cordone G, Tabaton M, Wolozin B, Ghanbari H (2003) Oxidative damage in the olfactory system in Alzheimer's disease. Acta Neuropathol (Berl) 106, 552-556. (Pubitemid 37441611)
86. Smith MA, Siedlak SL, Richey PL, Nagaraj RH, Elhammer A, Perry G (1996) Quantitative solubilization and analysis of insoluble paired helical filaments from Alzheimer disease. Brain Res 717, 99-108. (Pubitemid 26153441)
87. Liu Q, Xie F, Rolston R, Moreira PI, Nunomura A, Zhu X, Smith MA, Perry G (2007) Prevention and treatment of Alzheimer disease and aging: antioxidants. Mini Rev Med Chem 7, 171-180. (Pubitemid 46592180)
88. Dimakopoulos AC (2005) Protein aggregation in Alzheimer's disease and other neoropathological disorders. Curr Alzheimer Res 2, 19-28. (Pubitemid 41389256)
89. Larbig G, Pickhardt M, Lloyd DG, Schmidt B, Mandelkow E (2007) Screening for inhibitors of tau protein aggregation into Alzheimer paired helical filaments: a ligand based approach results in successful scaffold hopping. Curr Alzheimer Res 4, 315-323. (Pubitemid 47025430)
90. Webster J, Urban C, Berbaum K, Loske C, Alpar A, Gartner U, de Arriba SG, Arendt T, Munch G (2005) The carbonyl scavengers aminoguanidine and tenilsetam protect against the neurotoxic effects of methylglyoxal. Neurotox Res 7, 95-101.
91. Booth AA, Khalifah RG, Hudson BG (1996) Thiamine pyrophosphate and pyridoxamine inhibit the formation of antigenic advanced glycation end-products: comparison with aminoguanidine. Biochem Biophys Res Commun 220, 113-119. (Pubitemid 126351245)
92. Rahbar S, Yerneni KK, Scott S, Gonzales N, Lalezari I (2000) Novel inhibitors of advanced glycation endproducts (part II). Mol Cell Biol Res Commun 3, 360-366. (Pubitemid 30803128)
93. Thomas MC, Baynes JW, Thorpe SR, Cooper ME(2005) The role of AGEs and AGE inhibitors in diabetic cardiovascular disease. Curr Drug Targets 6, 453-474. (Pubitemid 40916272)
94. Adrover M, Vilanova B, Frau J, Munoz F, Donoso J (2008) The pyridoxamine action on Amadori compounds: A reexamination of its scavenging capacity and chelating effect. Bioorg Med Chem 16, 5557-5569. (Pubitemid 351699280)
95. Nakamura S, Li H, Adijiang A, Pischetsrieder M, Niwa T (2007) Pyridoxal phosphate prevents progression of diabetic nephropathy. Nephrol Dial Transplant 22, 2165-2174. (Pubitemid 47244693)
96. Ahmed N, Thornalley PJ (2007) Advanced glycation endproducts: what is their relevance to diabetic complications? Diabetes Obes Metab 9, 233-245. (Pubitemid 46502041)
97. Reddy VP, Garrett MR, Perry G, Smith MA (2005) Carnosine: a versatile antioxidant and antiglycating agent. Sci Aging Knowledge Environ 2005, pe12.
98. Hipkiss AR (2007) Could carnosine or related structures suppress Alzheimer's disease? J Alzheimers Dis 11, 229-240.
99. Bruno S, Cattaneo D, Perico N, Remuzzi G (2005) Emerging drugs for diabetic nephropathy. Expert Opin Emerg Drugs 10, 747-771.
100. Wada R, Nishizawa Y, Yagihashi N, Takeuchi M, Ishikawa Y, Yasumura K, Nakano M, Yagihashi S (2001) Effects of OPB-9195, anti-glycation agent, on experimental diabetic neuropathy. Eur J Clin Invest 31, 513-520. (Pubitemid 32579388)
101. Susic D (2007) Cross-link breakers as a new therapeutic approach to cardiovascular disease. Biochem Soc Trans 35, 853-856. (Pubitemid 350206381)
102. Bhatwadekar A, Stitt AW (2007) AGE and RAGE inhibitors in the treatment of diabetic retinopathy. Expert Rev Ophthalmol 2, 105-120.
103. Peppa M, Brem H, Cai W, Zhang JG, Basgen J, Li Z, Vlassara H, Uribarri J (2006) Prevention and reversal of diabetic nephropathy in db/db mice treated with alagebrium (ALT-711). Am J Nephrol 26, 430-436. (Pubitemid 44971733)
104. Vasdev S, Gill V, Singal P (2007) Role of advanced glycation end products in hypertension and atherosclerosis: therapeutic implications. Cell Biochem Biophys 49, 48-63. (Pubitemid 47415346)
105. Devangelio E, Santilli F, Formoso G, Ferroni P, Bucciarelli L, Michetti N, Clissa C, Ciabattoni G, Consoli A, Davi G (2007) Soluble RAGE in type 2 diabetes: association with oxidative stress. Free Radic Biol Med 43, 511-518. (Pubitemid 47058227)
106. Prasad K (2006) Soluble receptor for advanced glycation end products (sRAGE) and cardiovascular disease. Int J Angiol 15, 57-68.
107. Tan KC, Chow WS, Tso AW, Xu A, Tse HF, Hoo RL, Betteridge DJ, Lam KS (2007) Thiazolidinedione increases serum soluble receptor for advanced glycation end-products in type 2 diabetes. Diabetologia 50, 1819-1825. (Pubitemid 47222871)
108. Tan KC, Shiu SW, Chow WS, Leng L, Bucala R, Betteridge DJ (2006) Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes. Diabetologia 49, 2756-2762.
109. Humpert PM, Papadopoulos G, Schaefer K, Djuric Z, Konrade I, Morcos M, Nawroth PP, Bierhaus A (2007) sRAGE and esRAGE are not associated with peripheral or autonomic neuropathy in type 2 diabetes. Horm Metab Res 39, 899-902.
110. Rottkamp CA, Raina AK, Zhu X, Gaier E, Bush AI, Atwood CS, Chevion M, Perry G, Smith MA (2001) Redox-active iron mediates amyloid-beta toxicity. Free Radic Biol Med 30, 447-450. (Pubitemid 32155543)
111. Moreira PI, Zhu X, Smith MA, Perry G, Nunomura A (2006) Antioxidant therapies in the prevention and treatment of Alzheimer disease In Oxidative Stress and Age-Related Neurodegeneration, Luo Y, Packer L, eds. Taylor & Francis Group, Boca Raton, pp. 131-145.